Chen WT, Huang F, Shiu CS, Lin SH, Tun MS, Nwe TW, Oo YTN, Oo HN Can social support mediate stigma and perceived stress in people live with human immunodeficiency virus? AIDS Care. 2024 Feb;36(2):255-262. doi: 10.1080/09540121.2023.2254545. Epub 2023 Sep 6.
Chen WT, Shiu C, Lee FR, Moolphate S, Aung MN Infrastructure collapsed, health care access disrupted, Myanmar people with chronic diseases are in danger. J Glob Health. 2023 Jan 11;13:03002. doi: 10.7189/jogh.13.03002. No abstract available.
Chen WT, Sun W, Huang F, Shiu CS, Kim B, Candelario J, Toma L, Wu G, Ah-Yune J Lost in Translation: Impact of Language Barriers and Facilitators on the Health Care of Asian Americans Living with HIV. J Racial Ethn Health Disparities. 2023 Jun 12:10.1007/s40615-023-01674-7. doi: 10.1007/s40615-023-01674-7. Online ahead of print.
Huang F, Chen WT, Lin SH, Tun MS, Nwe TW, Oo YTN, Oo HN Translation, Adaption, and Psychometric Testing of the Myanmar Version of the Medical Outcomes Study Social Support Survey for People Living With HIV/AIDS. Front Psychol. 2021 Sep 7;12:707142. doi: 10.3389/fpsyg.2021.707142. eCollection 2021.
Huang F, Chen WT, Shiu CS, Lin SH, Tun MS, Nwe TW, Nu Oo YT, Oo HN Adaptation and Validation of the Cognitive and Affective Mindfulness Scale-Revised (CAMS-R) in People Living with HIV in Myanmar. Mindfulness (N Y). 2022;13(1):188-197. doi: 10.1007/s12671-021-01784-5. Epub 2021 Nov 9.
Huang F, Chen WT, Shiu CS, Lin SH, Tun MS, Nwe TW, Oo YTN, Oo HN The Mediating Effects of Mindfulness on Perceived Stress From HIV Stigma in People Living With HIV in Myanmar: A Cross-sectional Study. J Assoc Nurses AIDS Care. 2022 Sep-Oct 01;33(5):559-566. doi: 10.1097/JNC.0000000000000352. Epub 2022 Jul 21.
Buddhist Understanding and Reduction of Myanmar Experiences of HIV Stigma and Exclusion
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
